Tissue Expression of Krüppel-Like Factors 4 and 7 in Bone Tumors
The Prognostic Value of Tissue Expression of Krüppel-Like Factors 4 and 7 in Bone Tumors
1 other identifier
observational
30
1 country
2
Brief Summary
The current study is to assess the prognostic value of Krüppel-like factors 4 and 7 in bone tumors, and its role in the disease progression.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Aug 2024
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 16, 2024
CompletedFirst Submitted
Initial submission to the registry
January 5, 2025
CompletedFirst Posted
Study publicly available on registry
April 20, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2026
CompletedApril 20, 2025
April 1, 2025
1.3 years
January 5, 2025
April 12, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The prognostic value
Assess the prognostic value of Krüppel-like factors 4 and 7 in bone tumors,
1 year
Study Arms (1)
Prospective Arm
Children, young adolescents younger than 15 years, and young adults (15 to 39 years) with histologically confirmed patients with skeletal or extra-skeletal OS or ES with localized or metastatic disease stages.
Interventions
Immunohistochemical staining of 4 um sections prepared from paraffin blocks using KLF factor (4 and 7) by automated immunostaining using the streptavidin-biotin technique.
Eligibility Criteria
Children, adolescents, and young adults diagnosed with localized and metastatic both skeletal and extra-skeletal osteosarcoma and Ewing's sarcoma
You may qualify if:
- Age: children, young adolescents younger than 15 years, and young adults (15 to 39 years) Gender: Males and female. Histologically confirmed patients with skeletal or extra-skeletal OS or ES. Both localized and metastatic disease stages.
You may not qualify if:
- Patients with second malignant bone sarcoma. Patients with benign bone tumors.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Ain Shams University
Cairo, 11566, Egypt
Faculty of Medicine Ain Shams Research Institute- Clinical Research Center (MASRI-CRC)
Cairo, 11566, Egypt
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Fatma S E Ebeid
Faculty of Medicine Ain Shams University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 5, 2025
First Posted
April 20, 2025
Study Start
August 16, 2024
Primary Completion
December 1, 2025
Study Completion
February 1, 2026
Last Updated
April 20, 2025
Record last verified: 2025-04
Data Sharing
- IPD Sharing
- Will not share